RxDoctor Payments Data

Brian Glaser, DO

Family Medicine · Flower Mound, TXNPI 1083672067

Payments from drug & device makers

$9,537in general payments, 2019–2025

Across 613 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Amgen$760
  • GSK$759
  • Pfizer$615
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$9,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,537 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$91,161
Medicare patients
282
Services billed
7,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$129,033
JardianceEmpagliflozin104$115,635
MounjaroTirzepatide28$38,937
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$35,735
TrulicityDulaglutide23$32,362
FarxigaDapagliflozin Propanediol36$29,966
EliquisApixaban26$28,146
XareltoRivaroxaban14$16,888
Repatha SureclickEvolocumab12$6,558
Testosterone16$5,722
Rosuvastatin Calcium305$4,119
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,419
Ezetimibe101$2,452
Gabapentin92$2,077
LantusInsulin Glargine,hum.Rec.Anlog13$1,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,197$129,03379 claims
Boehringer IngelheimJardiance$457$115,635104 claims
Lilly USA, LLCMounjaro, Trulicity$434$71,29951 claims
GSKTrelegy Ellipta, Shingrix$759$39,15355 claims
AstraZenecaFarxiga$1,454$29,96636 claims
PfizerEliquis$615$28,14626 claims
Johnson & JohnsonXarelto$40$16,88814 claims
Sanofi-aventis U.S. LLCLantus$157$1,70413 claims
AbbVieSynthroid$1,032$53720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Flower Mound

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →